title: Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
authors.forename: R
authors.initials: R
authors.lastname: Palacios
authors.forename: A
authors.initials: A
authors.lastname: Rivero
authors.forename: I
authors.initials: I
authors.lastname: Santos
authors.forename: M J
authors.initials: MJ
authors.lastname: Ríos
authors.forename: M
authors.initials: M
authors.lastname: Castaño
authors.forename: A
authors.initials: A
authors.lastname: del Arco
authors.forename: Jesús
authors.initials: J
authors.lastname: Santos González
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000633:toxicity; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016049:Didanosine / Q000008:administration & dosage / Q000633:toxicity*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D005215:Fasting; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood*; D008111:Liver Function Tests; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000633:toxicity; D000068698:Tenofovir; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D008055:Lipids; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D003841:Deoxycytidine; D019259:Lamivudine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine; D016049:Didanosine